TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01470989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885
Description: canakinumab 150 mg s.c., given on demand upon new flares

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 40 mg
Description: Participants received 40 mg intramuscular (IM)
Study: NCT02133443

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PSV - pressure support ventilation
Description: Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden). Pressure support ventilator assistance to obtain a tidal volume of 6-8 ml/kg of ideal body weight.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurally Adjusted Ventilatory Assist
Description: Partial ventilator support partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. Stepwise implementation of the NAVA level (steps of 25% ), returning to the  optimal  level between each evaluation (PSV 100%, NAVA 100%, 75%, 50%, 125%, 150%).
Study: NCT03817450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Mouth Care
Description: Nursing assistants will be trained to provide daily mouth care to all residents in nursing homes. Mouth care supplies will also be provided to intervention nursing homes.
Study: NCT00716950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan/amlodpine
Description: tablets; 160mg/5mg; od; 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan/amlodpine
Description: tablets; 100mg/5mg; od; 4 weeks
Study: NCT01706900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incubator Temp set to 36.5 degree
Description: We will set incubator Temp to 36.5 so we can assess the outcome and compare the results with the placebo group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Incubator Temp 37 degree
Description: We will set incubator Temp to 37 degree as the routine embryo culture Temp since 1978 as the placebo arm.
Study: NCT00266565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: 10mg/kg (max 750 ml) once a month for 3 months
Study: NCT04503915

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: different estrogen supplementation modes
Description: The different estrogen supplementation modes are randomized into two groups.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: different estrogen supplementation modes
Description: The different estrogen supplementation modes are randomized into two groups.
Study: NCT04545944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: 20 mg tablets administered orally
Study: NCT05484193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH agonist
Description: GnRH agonist alone for luteal phase support in fresh IVF embryo transfer cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: vaginal progesterone for luteal phase support
Study: NCT01815645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ST+CM
Description: 12 weeks of the standard treatment offered by a open treatment service for drug addiction of the city of Sao Paulo (AME) plus Contingency Management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: 12 weeks of standard treatment offered by AME (a open treatment service for drug addiction of the city of Sao Paulo)
Study: NCT04080011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NP-PWD
Description: Application of NP-PWD device.
Study: NCT00885365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tobramycin / Bramitob
Description: 300mg/4ml solution, via a nebuliser, over a 4-week treatment in a twice-daily regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tobramycin / TOBI
Description: 300mg/5ml solution administered via nebuliser, over a 4-week treatment in a twice-daily regimen
Study: NCT04328506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082 tablet (test product)
Description: Test product(T)：100mg CM082 tablet manufactured by Betta Pharmaceuticals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082 tablet (test product)
Description: Test product(T)：100mg CM082 tablet manufactured by Betta Pharmaceuticals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082 tablet (test product)
Description: Test product(T)：100mg CM082 tablet manufactured by Betta Pharmaceuticals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082 tablet (test product)
Description: Test product(T)：100mg CM082 tablet manufactured by Betta Pharmaceuticals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082 tablet (reference product)
Description: Reference product(R)：100mg CM082 tablet manufactured by Catalent Pharma Solutions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082 tablet (reference product)
Description: Reference product(R)：100mg CM082 tablet manufactured by Catalent Pharma Solutions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082 tablet (reference product)
Description: Reference product(R)：100mg CM082 tablet manufactured by Catalent Pharma Solutions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082 tablet (reference product)
Description: Reference product(R)：100mg CM082 tablet manufactured by Catalent Pharma Solutions
Study: NCT01982825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online intervention arm
Description: See online intervention arm

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online control arm
Description: See online control arm
Study: NCT03217851

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Collection
Description: blood smear and/or rapid diagnostic

Intervention type: DIAGNOSTIC_TEST
Intervention: Dried Blood Spot
Description: Dried Blood Spot on filter paper
Study: NCT02405533

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AHCC 3 grams once a day
Description: AHCC supplementation x 6 months with Placebo x 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplementation x 12 months
Study: NCT01085682

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling
Description: In intervention group, counseling sessions are conducted weekly for 3 months, once per two weeks for 3 months, monthly for 18 months, and then once every two months for the remainder of the study.
Study: NCT02272647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM Saline Placebo (0.25 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM Saline Placebo (0.25 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM Estradiol valerate (2.5 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM Estradiol valerate (2.5 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM Saline Placebo (0.5 ml)
Study: NCT01085682

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: In standard care group, counseling sessions are conducted only 6 times for 4 years
Study: NCT02272647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM Saline Placebo (0.5 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM Estradiol valerate (5.0 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM Estradiol valerate (5.0 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Micronized Progesterone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Micronized Progesterone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ghrelin (0.3 ug/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ghrelin (0.3 ug/kg)
Study: NCT02563301

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscopy
Description: After establishing full monitoring, inducing general anaesthesia and ensuring paralysis, laryngoscopy is performed and the patient's trachea is intubated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscopy
Description: After establishing full monitoring, inducing general anaesthesia and ensuring paralysis, laryngoscopy is performed and the patient's trachea is intubated.
Study: NCT02041962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Care Model for Mood Disorders
Description: The mood disorders CCM intervention (Life Goals Collaborative Care) consists of: (a) a web-based patient self-management skills enhancement (CCM-1), (b) enhanced information flow and continuity of care via a care manager (CCM-2), and (c) decision support, or situation-specific evidence-based clinical practice guideline recommendations for providers (CCM-3). The CCM will be implemented utilizing telephonic contact with patients and providers by an Aetna care managers.The care managers will also use the Life Goals web portal as a guide for each session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Control
Study: NCT01886118

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy
Description: A luteal phase endometrial biopsy will be performed in the cycle prior to the patient's In Vitro Fertilization stimulation cycle using a standard Pipelle Endometrial Suction curette in all participants between days ovulation+5 and ovulation+7 of the cycle preceding the stimulation cycle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial biopsy
Description: A luteal phase endometrial biopsy will be performed in the cycle prior to the patient's In Vitro Fertilization stimulation cycle using a standard Pipelle Endometrial Suction curette in all participants between days ovulation+5 and ovulation+7 of the cycle preceding the stimulation cycle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Endometrial Co-Culture
Description: embryos will be transferred to Endocell co-culture media for Autologous Endometrial Co-Culture between day 2 and day 5

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional media culture
Description: embryos are cultured in conventional media
Study: NCT01923025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5545965
Description: Single dose
Study: NCT03614572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group MI
Description: refer to the arm description
Study: NCT01447394

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Lambda
Description: Syringe, Subcutaneous, 180 μg, Once weekly, 48 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon Alfa-2a
Description: Syringe, Subcutaneous, 180 μg, Once weekly, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks
Study: NCT03258814

Intervention type: BEHAVIORAL
Intervention: Active Supervised Training (AST)
Description: The active supervised and standardized training consisted of 24 units of exercise within 20 weeks performed in certified training centers and was focused on back fitness, core strengthening and patient engagement to treat back pain and functional impairment.

Intervention type: BEHAVIORAL
Intervention: Standard of Care (SOC) Physiotherapy
Description: Standard of care physiotherapy as used in this study included active as well as passive training and massages according to the physiotherapist discretion.
Study: NCT00813995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Sitagliptin phosphate
Description: All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate 100 mg tablets once daily (q.d.) and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate placebo tablets q.d. and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.
Study: NCT02507349

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Person-Centered Care
Description: Decision support center staffed by peers. Patient uses the CommonGround program prior to medication visit to prepare a personal report, with support from peer(s). The CommonGround report expresses goals for medication, how other strategies help with functioning, current problems, and medication side effects. Patient brings report into the medication visit. Prescriber and patient discuss medication options, and prescriber enters the shared decision into CommonGround during the visit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Measurement-Based Care
Description: Clinic staff asks each patient to use a tablet computer to complete a brief assessment of symptoms and problems prior to medication visit. Prescriber views assessment results on office computer and discusses next steps in medication management with the patient.
Study: NCT01130506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT01583348

Intervention type: PROCEDURE
Intervention: Cholangiography during transvaginal rigid-hybdrid NOTES cholecystectomy
Description: During transvaginal rigid-hybrid NOTES cholecystectomy a intraoperative cholangiography is performed. After dissection of the Calot's triangle and distal clipping of the cystic duct, the cystic duct is incised and a regular cholangiography catheter is inserted. Contrast is injected and an image is obtained using an image-converter. After extraction of the catheter the cystic duct is clipped proximally. This intervention is performed in all patients included in the study.
Study: NCT02082197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-SLV176
Description: ABT-SLV176 administered daily
Study: NCT04523662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab Apatinib Mesylas
Description: This study intends to use the PD-1 antibody carrelizumab combined with apatinib and radiotherapy to treat patients with advanced liver cancer with extrahepatic metastasis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab Apatinib Mesylas
Description: This study intends to use the PD-1 antibody carrelizumab combined with apatinib and radiotherapy to treat patients with advanced liver cancer with extrahepatic metastasis
Study: NCT02272647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ghrelin (0.3 ug/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ghrelin (0.3 ug/kg)
Study: NCT02809586

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMI + I
Description: This 8-week social media based intervention consists of e-coaches delivering positive content to facilitate peer interaction. Participants will earn incentives for interaction during the intervention (8 weeks).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMI
Description: This 8-week social media based intervention consists of e-coaches delivering positive content to facilitate peer interaction. This group will NOT receive incentives for their participation in the secret group.
Study: NCT02584764

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Study: NCT04545944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 2 mg syrup administered orally
Study: NCT02434601

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Treatment of Dentin Surface
Description: * Experimental Group 1: Increase the etching time to 30 seconds, performed with phosphoric acid gel at 37%, prior to application of the resin adhesive.~* Experimental Group 2: Prophylaxis cavity probe / blunt tip of ultrasound, applied for 30 seconds on the dentin surface hypermineralized of cervical lesions non-carious.~Both restorative procedures were performed using a conventional adhesive system and composite restorative nanoparticulate.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dentin Surface
Description: Treatment of Dentin Surface: Increased etching dentin for 15 seconds to 30 seconds

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Treatment of Dentin Surface: Intervention with the cavity prophylaxis probe ultrasound blunt applied for 30 seconds in Surface hypermineralized non-carious dentin cervical lesions. Therefore, the restoration was done following the protocol recommended by the manufacturer of the material.
Study: NCT02019901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-led clinic
Study: NCT04434378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: 0.4 mg tamsulosin will be given to a randomized group of patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo will be given to a randomized group of patients
Study: NCT01426789

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to secukinumab I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: In part 1 (blinded period), participants randomized to secukinumab received 10 mg/kg I.V.. Participants, enrolled in part 2 (open label), received secukinumab 300 mg subcutaneous.
Study: NCT00586664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepreve (bepotastine besilate ophthalmic solution) 1.5%
Description: sterile ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: sterile ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepotastine Besilate Ophthalmic Solution 1.0%
Description: sterile ophthalmic solution
Study: NCT04148872

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Retraining Therapy (4 months)
Description: Neuromuscular retraining is an intervention where facial therapists utilize voluntary input to access improved movement patterns in patients with synkinesis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemodenervation (4 months)
Description: A neurotoxin that temporarily reduces muscle activity and minimizes the effects of uncoordinated muscle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Retraining + Chemodenervation
Description: Participants will receive both interventions for the last 4 months of their time on study.
Study: NCT02584764

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet support
Study: NCT03266471

Intervention type: DIAGNOSTIC_TEST
Intervention: Baseline blood sample
Description: Blood sample for cytokine measurements and genetics.

Intervention type: DIAGNOSTIC_TEST
Intervention: Baseline blood sample
Description: Blood sample for cytokine measurements and genetics.

Intervention type: DIAGNOSTIC_TEST
Intervention: Baseline intestinal biopsies
Description: Up to 20 additional biopsies will be obtained at the time of standard of care colonoscopy. It is not felt that additional biopsies substantially increases the risk of a colonoscopy. Cytokine measurements will be performed on the tissue collected.

Intervention type: DIAGNOSTIC_TEST
Intervention: Baseline intestinal biopsies
Description: Up to 20 additional biopsies will be obtained at the time of standard of care colonoscopy. It is not felt that additional biopsies substantially increases the risk of a colonoscopy. Cytokine measurements will be performed on the tissue collected.

Intervention type: OTHER
Intervention: Crohn's disease activity index (CDAI)
Description: To determine response, a Crohn's Disease Activity Index (CDAI) score will be obtained at time point 1 and time point 2 in all enrolled CD patients. The CDAI is a well validated symptom index for CD which assesses 8 factors including stool frequency, abdominal pain, general well being, CD complications, HCT, and deviation from ideal body weight.

Intervention type: DIAGNOSTIC_TEST
Intervention: Post treatment blood sample
Description: Blood sample for cytokine measurements after patients have been on therapy for at least 6 weeks but no more than 52 weeks.

Intervention type: DIAGNOSTIC_TEST
Intervention: Post treatment intestinal biopsies
Description: Up to 20 additional biopsies will be obtained at the time of standard of care colonoscopy at least 6 weeks but no more than 52 weeks after initiation of therapy. It is not felt that additional biopsies substantially increases the risk of a colonoscopy. Cytokine measurements will be performed on the tissue collected.

Intervention type: DIAGNOSTIC_TEST
Intervention: Baseline stool sample
Description: Stool sample for inflammatory markers or microbiome analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Baseline stool sample
Description: Stool sample for inflammatory markers or microbiome analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Post treatment stool sample
Description: Stool sample for inflammatory markers or microbiome analysis.
Study: NCT04217993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib hydrochloride tablets
Description: Jaktinib hydrochloride tablets 100mg twice dose group，Jaktinib hydrochloride tablets 150mg qd dose group, Jaktinib hydrochloride tablets 200mg qd dose group and Jaktinib hydrochloride tablets 100mg qd dose group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib hydrochloride tablets
Description: Jaktinib hydrochloride tablets 100mg twice dose group，Jaktinib hydrochloride tablets 150mg qd dose group, Jaktinib hydrochloride tablets 200mg qd dose group and Jaktinib hydrochloride tablets 100mg qd dose group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib hydrochloride tablets
Description: Jaktinib hydrochloride tablets 100mg twice dose group，Jaktinib hydrochloride tablets 150mg qd dose group, Jaktinib hydrochloride tablets 200mg qd dose group and Jaktinib hydrochloride tablets 100mg qd dose group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib hydrochloride tablets
Description: Jaktinib hydrochloride tablets 100mg twice dose group，Jaktinib hydrochloride tablets 150mg qd dose group, Jaktinib hydrochloride tablets 200mg qd dose group and Jaktinib hydrochloride tablets 100mg qd dose group